NEW YORK (GenomeWeb) – Vermillion said yesterday that its Aspira Labs subsidiary has won out-of-state provider status with Medi-Cal, California’s Medicaid program, for its OVA1 ovarian cancer test.
The status gives the company access to more than 12 million Medi-Cal beneficiaries, representing roughly one-third of the covered lives in California, Vermillion said.
Get the full story This story is free
for registered users
Registering provides access to this and other free content.
Already have an account?